Mechanisms Involved in 3 `,5 `-Cyclic Adenosine Monophosphate-Mediated Inhibition of the Ubiquitin-Proteasome System in Skeletal Muscle
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
19/10/2012
19/10/2012
2009
|
Resumo |
Although it is well known that catecholamines inhibit skeletal muscle protein degradation, the molecular underlying mechanism remains unclear. This study was undertaken to investigate the role of beta(2)-adrenoceptors (AR) and cAMP in regulating the ubiquitin-proteasome system (UPS) in skeletal muscle. We report that increased levels of cAMP in isolated muscles, promoted by the cAMP phosphodiesterase inhibitor isobutyl methylxanthine was accompanied by decreased activity of the UPS, levels of ubiquitin-protein conjugates, and expression of atrogin-1, a key ubiquitin-protein ligase involved in muscle atrophy. In cultured myotubes, atrogin-1 induction after dexamethasone treatment was completely prevented by isobutyl methylxanthine. Furthermore, administration of clenbuterol, a selective beta(2)-agonist, to mice increased muscle cAMP levels and suppressed the fasting-induced expression of atrogin-1 and MuRF-1, atrogin-1 mRNA being much more responsive to clenbuterol. Moreover, clenbuterol increased the phosphorylation of muscle Akt and Foxo3a in fasted rats. Similar responses were observed in muscles exposed to dibutyryl-cAMP. The stimulatory effect of clenbuterol on cAMP and Akt was abolished in muscles from beta(2)-AR knockout mice. The suppressive effect of beta(2)-agonist on atrogin-1 was not mediated by PGC-1 alpha (peroxisome proliferator-activated receptor-gamma coactivator 1 alpha known to be induced by beta(2)-agonists and previously shown to inhibit atrogin-1 expression), because food-deprived PGC-1 alpha knockout mice were still sensitive to clenbuterol. These findings suggest that the cAMP increase induced by stimulation of beta(2)-AR in skeletal muscles from fasted mice is possibly the mechanism by which catecholamines suppress atrogin-1 and the UPS, this effect being mediated via phosphorylation of Akt and thus inactivation of Foxo3. (Endocrinology 150: 5395-5404, 2009) Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)[08/06694-6] Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)[04/02674-0] Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)[06/06974-3] Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)[09/07584-2] Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)[305847/06-6] Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)[300440/05-7] Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)[130866/2007-5] Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)[140094/2007-5] Fonds de la recherche en santedu Quebec Canadian Institutes of Health Research |
Identificador |
ENDOCRINOLOGY, v.150, n.12, p.5395-5404, 2009 0013-7227 http://producao.usp.br/handle/BDPI/23770 10.1210/en.2009-0428 |
Idioma(s) |
eng |
Publicador |
ENDOCRINE SOC |
Relação |
Endocrinology |
Direitos |
restrictedAccess Copyright ENDOCRINE SOC |
Palavras-Chave | #TUMOR-BEARING RATS #IN-VIVO #PROTEIN-KINASE #ATROPHY #ACTIVATION #EXPRESSION #CAMP #PGC-1-ALPHA #ATROGIN-1 #EXERCISE #Endocrinology & Metabolism |
Tipo |
article original article publishedVersion |